VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation

FRA:VX1 • US92532F1003

Current stock price

406.3 EUR
-4.9 (-1.19%)
Last:

This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. VX1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year VX1 was profitable.
  • In the past year VX1 had a positive cash flow from operations.
  • Of the past 5 years VX1 4 years were profitable.
  • Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • VX1 has a better Return On Assets (15.42%) than 91.25% of its industry peers.
  • Looking at the Return On Equity, with a value of 21.18%, VX1 belongs to the top of the industry, outperforming 91.25% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 15.14%, VX1 belongs to the top of the industry, outperforming 95.00% of the companies in the same industry.
  • VX1 had an Average Return On Invested Capital over the past 3 years of 15.82%. This is above the industry average of 11.34%.
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROIC 15.14%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • The Profit Margin of VX1 (32.94%) is better than 92.50% of its industry peers.
  • VX1's Profit Margin has declined in the last couple of years.
  • VX1 has a better Operating Margin (39.04%) than 92.50% of its industry peers.
  • VX1's Operating Margin has declined in the last couple of years.
  • The Gross Margin of VX1 (86.24%) is better than 75.00% of its industry peers.
  • VX1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. VX1.DE Health Analysis

2.1 Basic Checks

  • VX1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, VX1 has less shares outstanding
  • The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
  • Compared to 1 year ago, VX1 has an improved debt to assets ratio.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • VX1 has an Altman-Z score of 12.46. This indicates that VX1 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of VX1 (12.46) is better than 91.25% of its industry peers.
  • VX1 has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
  • VX1 has a better Debt to FCF ratio (0.03) than 100.00% of its industry peers.
  • VX1 has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • VX1 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. VX1 outperforms 91.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 12.46
ROIC/WACC1.7
WACC8.92%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.90 indicates that VX1 has no problem at all paying its short term obligations.
  • VX1 has a Current ratio (2.90) which is comparable to the rest of the industry.
  • A Quick Ratio of 2.46 indicates that VX1 has no problem at all paying its short term obligations.
  • VX1 has a Quick ratio of 2.46. This is in the better half of the industry: VX1 outperforms 61.25% of its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.46
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VX1.DE Growth Analysis

3.1 Past

  • VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
  • VX1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.27% yearly.
  • VX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.90%.
  • The Revenue has been growing by 14.10% on average over the past years. This is quite good.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
  • Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y5.3%
EPS Next 2Y9.43%
EPS Next 3Y10.17%
EPS Next 5Y12.36%
Revenue Next Year8.79%
Revenue Next 2Y9.46%
Revenue Next 3Y10.13%
Revenue Next 5Y10.31%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. VX1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 25.33 indicates a quite expensive valuation of VX1.
  • 78.75% of the companies in the same industry are more expensive than VX1, based on the Price/Earnings ratio.
  • VX1's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.96.
  • With a Price/Forward Earnings ratio of 24.05, VX1 is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 81.25% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 24.04. VX1 is around the same levels.
Industry RankSector Rank
PE 25.33
Fwd PE 24.05
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 78.75% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, VX1 is valued cheaply inside the industry as 82.50% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 37.09
EV/EBITDA 22.54
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VX1 does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of VX1 may justify a higher PE ratio.
PEG (NY)4.78
PEG (5Y)2.06
EPS Next 2Y9.43%
EPS Next 3Y10.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VX1.DE Dividend Analysis

5.1 Amount

  • No dividends for VX1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VX1.DE Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

FRA:VX1 (3/16/2026, 7:00:00 PM)

406.3

-4.9 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.75%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap103.21B
Revenue(TTM)12.00B
Net Income(TTM)3.95B
Analysts81.03
Price Target461.23 (13.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.17%
Min EPS beat(2)-2.79%
Max EPS beat(2)3.12%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)4
Avg EPS beat(8)-64.44%
EPS beat(12)6
Avg EPS beat(12)-43.04%
EPS beat(16)9
Avg EPS beat(16)-31.46%
Revenue beat(2)0
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-1.51%
Max Revenue beat(2)-1.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)0.06%
Revenue beat(8)3
Avg Revenue beat(8)-0.66%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-0.51%
PT rev (1m)2.72%
PT rev (3m)7.22%
EPS NQ rev (1m)-9.33%
EPS NQ rev (3m)-9.39%
EPS NY rev (1m)-4.91%
EPS NY rev (3m)-4.92%
Revenue NQ rev (1m)-1.91%
Revenue NQ rev (3m)-1.73%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 25.33
Fwd PE 24.05
P/S 9.87
P/FCF 37.09
P/OCF 32.62
P/B 6.35
P/tB 6.91
EV/EBITDA 22.54
EPS(TTM)16.04
EY3.95%
EPS(NY)16.89
Fwd EY4.16%
FCF(TTM)10.96
FCFY2.7%
OCF(TTM)12.46
OCFY3.07%
SpS41.17
BVpS64.03
TBVpS58.84
PEG (NY)4.78
PEG (5Y)2.06
Graham Number152.01
Profitability
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROCE 21.51%
ROIC 15.14%
ROICexc 24.16%
ROICexgc 27.17%
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
FCFM 26.61%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.92%
ROICexc(5y)41.25%
ROICexgc(3y)35.7%
ROICexgc(5y)59.25%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-36.41%
ROICexgc growth 5Y-24.43%
ROICexc growth 3Y-28.98%
ROICexc growth 5Y-17.32%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 208.58%
Cap/Sales 3.65%
Interest Coverage 377.85
Cash Conversion 74.18%
Profit Quality 80.79%
Current Ratio 2.9
Quick Ratio 2.46
Altman-Z 12.46
F-Score7
WACC8.92%
ROIC/WACC1.7
Cap/Depr(3y)195.12%
Cap/Depr(5y)182.1%
Cap/Sales(3y)3.56%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y5.3%
EPS Next 2Y9.43%
EPS Next 3Y10.17%
EPS Next 5Y12.36%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year8.79%
Revenue Next 2Y9.46%
Revenue Next 3Y10.13%
Revenue Next 5Y10.31%
EBIT growth 1Y6.59%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year6.57%
EBIT Next 3Y12.66%
EBIT Next 5Y11.43%
FCF growth 1Y426.56%
FCF growth 3Y-6.64%
FCF growth 5Y1.3%
OCF growth 1Y837.19%
OCF growth 3Y-4.2%
OCF growth 5Y2.22%

VERTEX PHARMACEUTICALS INC / VX1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 9 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 5.3% in the next year.